Related Experiment Video
Updated: Jan 24, 2026

Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Published on: May 5, 2022
Distinct mutational landscape of inverted urothelial papilloma
Mahmut Akgul1, Gregory T MacLennan2, Liang Cheng3
1Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
A recent study has identified gene mutations involving the MAPK/ERK pathway, particularly the HRAS gene, in all inverted urothelial papillomas (IUPs), in the absence of pathway mutations in TERT promoter, FGFR3, and TP53/RB1genes. Neither recurrence nor progression was observed in IUPs. These data support several longstanding hypotheses: (1) IUPs are benign and do not recur or progress; (2) they harbor mutations that are different from those of urothelial carcinoma; and (3) they arise through different molecular mechanisms than low- or high-grade urothelial carcinoma. As the most critical differential diagnosis in this context is inverted-type urothelial carcinoma, more comprehensive studies are needed to compare and contrast these entities. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Insights
Inverted urothelial papillomas (IUPs) show HRAS gene mutations within the MAPK/ERK pathway. These benign tumors do not recur or progress, distinguishing them molecularly from urothelial carcinoma.
Area of Science:
- Uro-oncology
- Molecular pathology
- Genetics
Background:
- Inverted urothelial papillomas (IUPs) are rare bladder tumors.
- Distinguishing IUPs from urothelial carcinoma is critical for patient management.
- Previous studies suggested distinct molecular profiles for IUPs.
Purpose of the Study:
- To investigate the genetic landscape of inverted urothelial papillomas.
- To identify specific gene mutations associated with IUP development.
- To compare the molecular characteristics of IUPs with urothelial carcinoma.
Main Methods:
- Somatic mutation profiling of IUPs.
- Targeted sequencing of key oncogenes and tumor suppressors.
- Analysis of mutations in MAPK/ERK pathway, TERT promoter, FGFR3, and TP53/RB1 genes.
Main Results:
- All analyzed IUPs exhibited mutations in the MAPK/ERK pathway, specifically within the HRAS gene.
- No mutations were detected in TERT promoter, FGFR3, or TP53/RB1 genes in IUPs.
- No instances of recurrence or progression were observed in patients with IUPs.
Conclusions:
- IUPs are benign tumors that do not recur or progress.
- IUPs possess a distinct molecular signature, characterized by HRAS mutations, differentiating them from urothelial carcinoma.
- The findings support unique molecular pathways for IUP development compared to urothelial carcinoma.
Related Concept Videos
Inverting and Non-inverting OpAmps
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms

